City
Epaper

Liquid biopsy could prevent kidney transplant rejections, new study shows

By IANS | Updated: August 7, 2024 17:55 IST

New Delhi, Aug 7 Donor-derived cell-free DNA (dd-cfDNA), also known as liquid biopsy, has the potential for early ...

Open in App

New Delhi, Aug 7 Donor-derived cell-free DNA (dd-cfDNA), also known as liquid biopsy, has the potential for early detection of kidney transplant rejection, a new study shows.

The international study enrolled kidney transplant recipients - both adult and paediatric - from 14 transplantation centres in Europe and the US.

In inflammation associated with transplant rejection, dying cells release donor-derived cell-free DNA (dd-cfDNA) into the bloodstream.

Researchers found that dd-cfDNA levels were strongly correlated with different types of transplant rejection, including antibody-mediated rejection, T cell-mediated rejection, and mixed rejection. The study found similar accuracy in both children and adults.

Currently, unnecessary and invasive graft biopsies are considered the "gold standard" for diagnosing transplant rejection. However, dd-cfDNA could provide a non-invasive, accurate biomarker to reduce the need for biopsy.

Two Indian origin Washington University School of Medicine researchers Raja Dandamudi, MD, and Vikas Dharnidharka, MD, MPH, contributed to the study, led by researchers from the Universite Paris Cite and doctors from the Assistance Publique - Hopitaux de Paris.

"Many studies of newer biomarkers to detect acute rejection in kidney transplants are not very large and cannot study various sub-populations, limiting their generalizability," Dharnidharka said. This work was a very large international collaboration. The analyses demonstrated that dd-cfDNA improves the acute rejection detection beyond our standard of care monitoring, including in subpopulations of transplant recipients who are of African ancestry or of pediatric age."

"This paper advances our understanding of the benefits of using cf-DNA as a biomarker for rejection and outcomes in the field of kidney transplantation." said Tarek Alhamad, professor of Medicine at WashU Medicine.

While biopsies will continue as the method of rejection diagnosis, dd-cfDNA may improve early rejection diagnosis and enhance the care of kidney transplant recipients.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

Other SportsDPL 2025: Run-fest continues as New Delhi Tigers beat Outer Delhi Warriors in high-scoring thriller

NationalManipur govt expands police organisation to boost policing capability

NationalWater release from Narmada dam reduced amid lesser rain, inflow

EntertainmentNaveen Kasturia shares his childhood obsession

NationalCM Yogi leads flood relief drive, mobilises ministers across Uttar Pradesh

Technology Realted Stories

TechnologySouth Korean President Lee calls for measures to curb fake news on YouTube

TechnologyDPIIT ieam visits Bengaluru to boost IoT and Deep-Tech innovation

TechnologyIndia's smartphone exports hit record $7.72 billion in Q1FY26, Apple leads with $6 billion

TechnologyIndia’s chip market poised to scale $110 billion by 2030

TechnologyQ1 Earnings Review: Brokerages give mixed outlook, earnings downgrade ratio drops